JP2025517509A - 脊髄小脳失調症を治療する方法 - Google Patents

脊髄小脳失調症を治療する方法 Download PDF

Info

Publication number
JP2025517509A
JP2025517509A JP2024569498A JP2024569498A JP2025517509A JP 2025517509 A JP2025517509 A JP 2025517509A JP 2024569498 A JP2024569498 A JP 2024569498A JP 2024569498 A JP2024569498 A JP 2024569498A JP 2025517509 A JP2025517509 A JP 2025517509A
Authority
JP
Japan
Prior art keywords
dosage form
patient
weeks
administered
daily
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024569498A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025517509A5 (https=
Inventor
コリック，ウラジーミル
バイナー，メリッサ
クレシ，イルファン
リタリエン，ギルバート
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biohaven Therapeutics Ltd
Original Assignee
Biohaven Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biohaven Therapeutics Ltd filed Critical Biohaven Therapeutics Ltd
Publication of JP2025517509A publication Critical patent/JP2025517509A/ja
Publication of JP2025517509A5 publication Critical patent/JP2025517509A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2024569498A 2022-05-23 2023-05-23 脊髄小脳失調症を治療する方法 Pending JP2025517509A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263344917P 2022-05-23 2022-05-23
US63/344,917 2022-05-23
PCT/US2023/067326 WO2023230451A2 (en) 2022-05-23 2023-05-23 Methods of treating spinocerebellar ataxias

Publications (2)

Publication Number Publication Date
JP2025517509A true JP2025517509A (ja) 2025-06-05
JP2025517509A5 JP2025517509A5 (https=) 2026-04-03

Family

ID=88920175

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024569498A Pending JP2025517509A (ja) 2022-05-23 2023-05-23 脊髄小脳失調症を治療する方法

Country Status (5)

Country Link
EP (1) EP4529485A2 (https=)
JP (1) JP2025517509A (https=)
KR (1) KR20250020409A (https=)
CN (1) CN120018855A (https=)
WO (1) WO2023230451A2 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP2400349A1 (hu) * 2024-07-05 2026-01-28 Egis Gyógyszergyár Zrt. Troriluzole-hidroklorid-sók
WO2026062600A1 (en) * 2024-09-22 2026-03-26 Biohaven Therapeutics Ltd. Troriluzole for use in treating spinocerebellar ataxias

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3585900B1 (en) * 2017-02-22 2022-12-21 CRISPR Therapeutics AG Materials and methods for treatment of spinocerebellar ataxia type 2 (sca2) and other spinocerebellar ataxia type 2 protein (atxn2) gene related conditions or disorders
EP4483956B1 (en) * 2017-11-12 2025-12-31 Biohaven Therapeutics Ltd. TRORILUZOLE INTENDED FOR USE IN THE TREATMENT OF SPINOCEREBELLOUS ATAXIA 3 (SCA3)
US20210308111A1 (en) * 2018-07-27 2021-10-07 With Great Power, Llc Clinical Methods And Pharmaceutical Compositions Employing AMPA Receptor Antagonists To Treat Glioblastoma And Other Cancers
US20230067811A1 (en) * 2020-01-24 2023-03-02 University Of Virginia Patent Foundation Modulating lymphatic vessels in neurological disease

Also Published As

Publication number Publication date
EP4529485A2 (en) 2025-04-02
WO2023230451A3 (en) 2024-01-04
WO2023230451A2 (en) 2023-11-30
KR20250020409A (ko) 2025-02-11
CN120018855A (zh) 2025-05-16

Similar Documents

Publication Publication Date Title
US10537566B2 (en) Combinations comprising siponimod and laquinimod for the treatment of multiple sclerosis
US20110130466A1 (en) Use of rasagiline for the treatment of progressive supranuclear palsy
JP2025517509A (ja) 脊髄小脳失調症を治療する方法
US10285981B2 (en) Compositions and methods for treating amyotrophic lateral sclerosis in responders
EP4483956B1 (en) TRORILUZOLE INTENDED FOR USE IN THE TREATMENT OF SPINOCEREBELLOUS ATAXIA 3 (SCA3)
KR20120050512A (ko) 탈수초를 갖는 환자에서 ４-아미노피리딘을 사용한 지속적 치료
Abelson et al. Comparative efficacy of olopatadine 0.1% ophthalmic solution versus levocabastine 0.05% ophthalmic suspension using the conjunctival allergen challenge model
US20260124183A1 (en) Methods of treating spinocerebellar ataxias
CA2753754C (en) Methods for treating schizophrenia
US20250375459A1 (en) Methods for ameliorating cognitive impairment using bile acid derivatives
WO2026062600A1 (en) Troriluzole for use in treating spinocerebellar ataxias
WO2026011229A1 (en) Novel therapy
WO2023243659A1 (ja) 線条体ストリオソームのドパミンｄ１シグナルを標的とした強迫性障害の薬物療法
HK40033906A (en) Use of riluzole prodrugs to treat ataxias
HK40033906B (en) Use of riluzole prodrugs to treat ataxias
Afshinmajd et al. Comparison the effects of Gabapentin and Propranolol in Patients with essential tremor
EA049071B1 (ru) Применение пролекарств рилузола для лечения атаксии
HK1160586A (en) Durable treatment with 4-aminopyridine in patients with demyelination

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260326

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260326